$1.87+0.10 (+5.65%)
Microbot Medical Inc.
Microbot Medical Inc. in the Healthcare sector is trading at $1.87 with a market capitalization of $132M. Wall Street consensus targets $7.00 (3 analysts), implying a +274.3% move over the next 12 months. The stock is currently near its 52-week low of $1.60, remaining 18.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105,000 | $0 | $0 | $0 | $0 |
| Gross Profit | $2,000 | β | β | β | $0 |
| Operating Income | -$4.32Mβ | -$4.14Mβ | -$3.86Mβ | -$3.72Mβ | -$3.02M |
| Net Income | -$3.67Mβ | -$3.46Mβ | -$3.58Mβ | -$3.50Mβ | -$2.60M |
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical sy...
Microbot Medical (MBOT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Microbot Medical (MBOT) delivered earnings and revenue surprises of +37.50% and -76.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
XRAY heads into Q1 earnings with U.S. softness, tariff pressure and transformation costs weighing on margins as investors watch for signs of stabilization.
InnovAge heads into fiscal Q3 earnings with strong growth momentum and margin gains, but seasonal cost pressures and fading Medicaid tailwinds may temper near-term upside.